Division of Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
JAMA Pediatr. 2022 Jul 1;176(7):690-698. doi: 10.1001/jamapediatrics.2022.1024.
Blood culture overuse in the pediatric intensive care unit (PICU) can lead to unnecessary antibiotic use and contribute to antibiotic resistance. Optimizing blood culture practices through diagnostic stewardship may reduce unnecessary blood cultures and antibiotics.
To evaluate the association of a 14-site multidisciplinary PICU blood culture collaborative with culture rates, antibiotic use, and patient outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This prospective quality improvement (QI) collaborative involved 14 PICUs across the United States from 2017 to 2020 for the Bright STAR (Testing Stewardship for Antibiotic Reduction) collaborative. Data were collected from each participating PICU and from the Children's Hospital Association Pediatric Health Information System for prespecified primary and secondary outcomes.
A local QI program focusing on blood culture practices in the PICU (facilitated by a larger QI collaborative).
The primary outcome was blood culture rates (per 1000 patient-days/mo). Secondary outcomes included broad-spectrum antibiotic use (total days of therapy and new initiations of broad-spectrum antibiotics ≥3 days after PICU admission) and PICU rates of central line-associated bloodstream infection (CLABSI), Clostridioides difficile infection, mortality, readmission, length of stay, sepsis, and severe sepsis/septic shock.
Across the 14 PICUs, the blood culture rate was 149.4 per 1000 patient-days/mo preimplementation and 100.5 per 1000 patient-days/mo postimplementation, for a 33% relative reduction (95% CI, 26%-39%). Comparing the periods before and after implementation, the rate of broad-spectrum antibiotic use decreased from 506 days to 440 days per 1000 patient-days/mo, respectively, a 13% relative reduction (95% CI, 7%-19%). The broad-spectrum antibiotic initiation rate decreased from 58.1 to 53.6 initiations/1000 patient-days/mo, an 8% relative reduction (95% CI, 4%-11%). Rates of CLABSI decreased from 1.8 to 1.1 per 1000 central venous line days/mo, a 36% relative reduction (95% CI, 20%-49%). Mortality, length of stay, readmission, sepsis, and severe sepsis/septic shock were similar before and after implementation.
Multidisciplinary diagnostic stewardship interventions can reduce blood culture and antibiotic use in the PICU. Future work will determine optimal strategies for wider-scale dissemination of diagnostic stewardship in this setting while monitoring patient safety and balancing measures.
儿科重症监护病房(PICU)中血液培养的过度使用会导致不必要的抗生素使用,并导致抗生素耐药性。通过诊断管理优化血液培养实践,可以减少不必要的血液培养和抗生素。
评估由 14 个多学科 PICU 组成的血液培养合作与培养率、抗生素使用和患者结局之间的关系。
设计、地点和参与者:这项前瞻性质量改进(QI)合作涉及美国 2017 年至 2020 年的 14 个 PICUs,参与了 Bright STAR(测试管理减少抗生素)合作。从每个参与的 PICU 以及儿童保健协会儿科健康信息系统收集了数据,以用于规定的主要和次要结果。
一项专注于 PICU 血液培养实践的本地 QI 计划(由更大的 QI 合作提供便利)。
主要结果是血液培养率(每 1000 患者日/月)。次要结果包括广谱抗生素使用(总治疗天数和新开始使用广谱抗生素≥3 天)和 PICU 中心静脉相关血流感染(CLABSI)、艰难梭菌感染、死亡率、再入院、住院时间、败血症和严重败血症/感染性休克的发生率。
在 14 个 PICU 中,实施前的血液培养率为每 1000 患者日/月 149.4 次,实施后的血液培养率为每 1000 患者日/月 100.5 次,相对减少了 33%(95%CI,26%-39%)。与实施前后的时间段相比,广谱抗生素使用的比率从 506 天降至 440 天/1000 患者日/月,相对减少了 13%(95%CI,7%-19%)。广谱抗生素起始率从 58.1 次降至 53.6 次/1000 患者日/月,相对减少了 8%(95%CI,4%-11%)。CLABSI 的发生率从每 1000 个中心静脉置管日 1.8 次降至 1.1 次,相对减少了 36%(95%CI,20%-49%)。死亡率、住院时间、再入院、败血症和严重败血症/感染性休克在实施前后相似。
多学科诊断管理干预措施可以减少 PICU 中的血液培养和抗生素使用。未来的工作将确定在这种情况下更广泛地传播诊断管理的最佳策略,同时监测患者安全并平衡措施。